Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.
Abstract: A cylinder-piston unit of a needle-free injector, with at least one cylinder accommodating an injection solution, at least one piston, and an adhesive coating arranged in the area of the free end face of the cylinder. The cylinder has a bottom portion, on which a discharge tube is arranged. An adhesive disc, which is displaceable in the direction of the center line of the cylinder-piston unit between an installation position and an application position, is arranged on the discharge tube and/or on the bottom portion. The adhesive disc has an adhesive coating on each of the two end faces. In the installation position, the discharge tube can be sealed off in the adhesive disc. In the application position, the front edge of the discharge nozzle lies in the plane of the front adhesive coating or protrudes beyond this plane by at least 0.5 mm.
Abstract: A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m2, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.
Abstract: The invention relates to the use of semi-fluorinated alkanes, in particular mixed with ethanol, as solubilising agents, permeation promoters and/or enhancers for lipophilic and/or poorly skin-permeable pharmaceutical agents that are administered via a transdermal therapeutic system (TTS), and to corresponding TTSs containing such substances.
Type:
Application
Filed:
May 7, 2015
Publication date:
June 29, 2017
Applicant:
LTS Lohmann Therapie-Systeme AG
Inventors:
Sandra WIEDERSBERG, Bernhard GÜNTHER, Dieter SCHERER
Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.
Abstract: A childproof packaging for individual doses, in particular for preparations for administration in film form, wherein the packaging constitutes a bag produced by sealing, which has a covering layer which is provided at each side of the packaging with local weak points which do not touch the edge of the packaging, wherein the local weak points form a cohesive pattern which runs around the individual dose in an arc or a curve and overlaps an angular region of at least 90° when considered from the main area of the individual zone. The local weak points have a start area and an end area which have a Y configuration when the local weak points on each side of the packaging are superposed.
Type:
Grant
Filed:
May 4, 2016
Date of Patent:
May 2, 2017
Assignee:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
Markus Krumme, Grace A. Behrend, Stephen J. Dodd
Abstract: Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of rotigotine base in a self-adhesive layer structure, comprising A) a backing layer, and B) a rotigotine-containing biphasic layer, the bi phasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or a polymer mixture, and b) an inner phase having a composition comprising rotigotine base, wherein the inner phase forms dispersed deposits in the outer phase, and wherein the inner phase comprises i. rotigotine base, and ii.
Abstract: The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.
Abstract: A method for producing a tightly sealed bag packaging and to a tightly sealed bag packaging having at least one perforation and a receiving area surrounded by a plate-shaped edge region for the inert packaging of a product containing active ingredients, wherein the bag packaging comprises cover films or cover film segments bounding the receiving area and forming the edge region. The cover films or cover film segments are each provided with a channel system having at least one channel. The channel system crosses the part of the cover film or the cover film segment covering the receiving area. At one end, each channel is provided with a branching into two channel branches, Furthermore, a slit is arranged between the two channel branches, interrupting a peripheral edge of the bag packaging.
Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, wherein the inner phase comprises the additive and an active agent dissolved therein, wherein the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, wherein the maintenance of the permeation rate is proportional to the amount of active agent in the biphasic layer.
Abstract: A method for producing childproof, highly inert individual dose packagings for transdermal therapeutic systems or film-like forms of administration in the form of a sealing edge bag that can be peeled back with a complete surrounding and continuous sealing surface, comprising two packaging elements, that are arranged on top of each other and form the upper side and the bottom side of a bag containing the product, wherein at least one layer of the packaging material elements is a metal layer and at least one packaging material element a film laminate with at least three-layer design; and the outer layer of the at least three-layer film laminate comprises at least one line-shaped weakening that is not touching the edge of the packaging on the upper and bottom side and the line-shaped weakening has a reduced resistance to tear for opening the packaging.
Abstract: An edible oral film strip dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
Abstract: A cylinder-piston unit, with at least one cylinder accommodating an injection solution and having an outlet opening, and with at least one piston. The cylinder, or a component mounted upstream of the cylinder, has an end face from which, during correct emptying of the cylinder-piston unit, a short cannula protrudes, which has an outlet opening at its free end. The outlet opening has a surface with a border which has a point near the bottom or an edge near the bottom. The point near the bottom or the edge near the bottom lies 0.15-0.3 mm away from the end face or the front-most point or edge thereof. A cylinder-piston unit is developed which is intended for a disposable injector and which is suitable for virtually painless penetration of the human skin, among other reasons for the administration of highly viscous injection solutions.
Abstract: A device and a method for determining a suitability of an active ingredient to be applied transdermally or transmucosally. In particular, a system that includes: at least one input device for inputting at least one designation of an active ingredient; a database for storing a plurality of data at least relating to the active ingredient; a computing unit for assessing a suitability of the active ingredient to be applied transdermally and/or transmucosally while taking into consideration data entered via the input device and/or data stored in the database; and an output device for displaying the assessed suitability.
Type:
Application
Filed:
February 24, 2015
Publication date:
February 16, 2017
Applicant:
LTS Lohmann Therapie-Systeme AG
Inventors:
Hanshermann Franke, Patrick Mohr, René Eifler, Marius Bauer
Abstract: The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.
Abstract: A microneedle system and method for production thereof. From a board a web grating is produced which has a plurality of grating nodes each defined by three apertures and which has web grating wedges. The microneedle system comprising a board and a plurality of openings delimited circumferentially by a web grating, having at each opening at least one web grating wedge having a needle-shaped tip which projects from the board and which is oriented at least approximately normal to the board. Web grating wedges having needle-shaped tips protrude into each aperture from at least three different directions. In order to produce openings, at least all the web grating wedges which protrude into an aperture are bent by a punch and the needle-shaped tips thereof are oriented normal to the plane of the web grating. At least two web grating wedges are arranged at each opening.
Abstract: A method for producing a tightly sealed bag packaging and to a tightly sealed bag packaging having at least one perforation and a receiving area surrounded by a plate-shaped edge region for the inert packaging of a product containing active ingredients, wherein the bag packaging comprises cover films or cover film segments bounding the receiving area and forming the edge region. The cover films or cover film segments are each provided with a channel system having at least one channel. The channel system crosses the part of the cover film or the cover film segment covering the receiving area. At one end, each channel is provided with a branching into two channel branches, Furthermore, a slit is arranged between the two channel branches, interrupting a peripheral edge of the bag packaging.
Abstract: A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m2, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m2. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.
Abstract: A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.
Type:
Grant
Filed:
August 22, 2012
Date of Patent:
November 8, 2016
Assignee:
LTS Lohmann Therapie-Systeme AG
Inventors:
Andreas Koch, Christoph Schmitz, Rolf Pracht, Mohammad Sameti
Abstract: The present invention relates to methods by which to produce sheet-like, wafer-like or film-like forms of drugs, confectionery, other food, cosmetics and the like for oral application or intake. The present invention is more particularly directed to the thermal treatment of carrier materials used in the production of such sheet-like, wafer-like or film-like forms. The thermal treatment removes contaminating or undesired substances from the carrier material.
Type:
Grant
Filed:
August 16, 2013
Date of Patent:
November 8, 2016
Assignee:
LTS Lohmann Therapie-Systeme AG
Inventors:
Detlev Neuland, Wolfgang Schaefer, Peter Schwarz